Submitted by Anonymous (not verified) on 17 February 2026 - 10:58
Human medicines European public assessment report (EPAR): Arexvy, recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E, Date of authorisation: 06/06/2023, Revision: 9, Status: Authorised
Source: